Sarepta (SRPT) Pops Higher as Glaxo's DMD Drug Drisapersen Falters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Sarepta (SRPT) May Seek Partner in Europe as Eteplirsen Tests Continue
January 11, 2013 9:21 AM ESTSarepta Therapeutics (Nasdaq: SRPT) is ticking higher amid chatter that it might seek to form an overseas partnership for its Duchenne muscular dystrophy (DMD)... More
